P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000971344.34270.c5 |
| _version_ | 1827331824636919808 |
|---|---|
| author | Jonathon Cohen Lindsey Roeker Chan Cheah Toby Eyre Krish Patel Jennifer Woyach John Seymour Michael Wang Yucai Wang Angely Loubert Nalin Payakachat Lisa Hess Paolo Abada Anthony R. Mato Paolo Ghia |
| author_facet | Jonathon Cohen Lindsey Roeker Chan Cheah Toby Eyre Krish Patel Jennifer Woyach John Seymour Michael Wang Yucai Wang Angely Loubert Nalin Payakachat Lisa Hess Paolo Abada Anthony R. Mato Paolo Ghia |
| author_sort | Jonathon Cohen |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:46:53Z |
| format | Article |
| id | doaj.art-141afaa557b54ed89782ff349bd546ff |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:46:53Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-141afaa557b54ed89782ff349bd546ff2024-03-03T06:25:11ZengWileyHemaSphere2572-92412023-08-017e34270c510.1097/01.HS9.0000971344.34270.c5202308003-01010P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDYJonathon Cohen0Lindsey Roeker1Chan Cheah2Toby Eyre3Krish Patel4Jennifer Woyach5John Seymour6Michael Wang7Yucai Wang8Angely Loubert9Nalin Payakachat10Lisa Hess11Paolo Abada12Anthony R. Mato13Paolo Ghia141 Emory Winship Cancer Institute, Atlanta, United States2 Memorial Sloan Kettering Cancer Center, New York, United States3 Linear Clinical Research and Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Australia4 Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom5 Hematology and Cellular Therapy Center, Swedish Cancer Institute, Seattle, United States6 The Ohio State University Comprehensive Cancer Center, Columbus, United States7 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Parkville, Australia8 MD Anderson Cancer Center Mays Clinic, Houston, United States9 Mayo Clinic Rochester MN, Rochester, United States10 Modus Outcomes, a Division of THREAD, Lyon, France11 Eli Lilly and Company, Indianapolis, United States11 Eli Lilly and Company, Indianapolis, United States12 Loxo@Lilly, Indianapolis, United States2 Memorial Sloan Kettering Cancer Center, New York, United States13 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italyhttp://journals.lww.com/10.1097/01.HS9.0000971344.34270.c5 |
| spellingShingle | Jonathon Cohen Lindsey Roeker Chan Cheah Toby Eyre Krish Patel Jennifer Woyach John Seymour Michael Wang Yucai Wang Angely Loubert Nalin Payakachat Lisa Hess Paolo Abada Anthony R. Mato Paolo Ghia P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY HemaSphere |
| title | P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY |
| title_full | P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY |
| title_fullStr | P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY |
| title_full_unstemmed | P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY |
| title_short | P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY |
| title_sort | p1112 patient reported outcomes pro among patients with mantle cell lymphoma receiving pirtobrutinib after prior covalent btki interim pro analysis from the bruin phase 1 2 study |
| url | http://journals.lww.com/10.1097/01.HS9.0000971344.34270.c5 |
| work_keys_str_mv | AT jonathoncohen p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT lindseyroeker p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT chancheah p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT tobyeyre p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT krishpatel p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT jenniferwoyach p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT johnseymour p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT michaelwang p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT yucaiwang p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT angelyloubert p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT nalinpayakachat p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT lisahess p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT paoloabada p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT anthonyrmato p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study AT paologhia p1112patientreportedoutcomesproamongpatientswithmantlecelllymphomareceivingpirtobrutinibafterpriorcovalentbtkiinterimproanalysisfromthebruinphase12study |